<DOC>
	<DOCNO>NCT00120705</DOCNO>
	<brief_summary>The purpose study assess ability darbepoetin alfa maintain hemoglobin concentration great equal 10 g/dL administer every 3 week ( Q3W ) .</brief_summary>
	<brief_title>Treatment Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects nonmyeloid malignancy Anemia ( screen hemoglobin concentration great equal 10.5 g/dL less equal 12.0 g/dL ) relate cancer chemotherapy At least 8 additional week cyclic chemotherapy plan regardless schedule Karnofsky Performance Status great equal 50 % Serum creatinine concentration less equal 2.0 mg/dL Exclusion Criteria : Iron deficiency Red blood cell ( RBC ) transfusion within 4 week screen Unstable cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>anemia</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>Amgen</keyword>
	<keyword>Non-myeloid Malignancies</keyword>
</DOC>